Anxiety-depressive disorders in patients with cardiovascular diseases in clinical practice: therapeutic options

September 28, 2018
963
Resume

The article examines the frequency of clinically expressed forms and subclinical manifestations of anxiety and depression in 153 patients with cardiovascular diseases. The effectiveness of therapy of anxiety and depression in these patients with Medopram for 6 months has been evaluated. A significant prevalence of anxiety-depressive disorders in patients with cardiovascular pathology has been confirmed, which indicates the necessity of incorporating standardized diagnostic methods into a comprehensive clinical and instrumental examination in patients for the timely detection of clinically significant anxiety and depression. High efficiency, safety, good tolerability and low potential of intermedicative interaction confirms the special importance of escitalopram (Medopram) in treatment of anxiety-depressive disorders in patients of all ages with cardiovascular diseases and gives grounds to consider it as a drug of choice in patients of this category in clinical practice.

T.V. Kolesnyk, A.V. Nadiuk, A.A. Kosova, M.G. Kyrychko, V.V. Beletsky

Key words: anxiety, depression, cardiovascular diseases, escitalopram, Medopram.

Published: 23.10.2018

References:

  • Burchinskiy S.G. (2018) Farmakoterapiya postinsultnoy depressii, problema i kriterii vyibora antidepressanta (neuronews.com.ua).
  • Vasyuk Yu.A., Dovzhenko T.V., Semiglazova M.V., Krasnov V.N. (2012) Trevozhno-depressivnyie rasstroystva i serdechno-sosudistyie zabolevaniya: klinicheskie vzaimosvyazi i sovremennyie podhodyi k terapii. Serdtse: zhurnal dlya praktikuyuschih vrachey, T. 11, 3(65): 155–164.
  • Gorina L.V. (2011) Sostoyanie trevogi i depressii u bolnyih s hronicheskoy serdechnoy nedostatochnostyu. … kand. dis. Orenburg, 108 s.
  • Dolzhenko M.N. (2013) Depressivnyie i trevozhnyie rasstroystva v kardiologii: vozmozhnosti kombinirovannoy terapii antidepressantom i antigipoksantom (www.mif-ua.com/archive/article/36740).
  • Maruta N.A., Moroz V.V. (2002) Nevroticheskie depressii (klinika, patogenez, diagnostika i lechenie). Aris, Harkov, 144 s.
  • Mihaylov B.V. (2003) Problema depressiy v obschesomaticheskoy praktike. med. zhurn., 9(3): 22–27.
  • Mosolov S.N., Kalinin V.V. (1998) Nekotoryie zakonomernosti formirovaniya, komorbidnost i farmakoterapiya trevozhno-fobicheskih rasstroystv. Trevoga i depressii. Moskva, s. 217–228.
  • Pinchuk I.Ya. (2010) Rasprostranennost psihicheskih rasstroystv v Ukraine. AMN Ukrainyi, 16(1): 168–176.
  • Samushiya M.A., Vecherinina K.O. (2005) Patoharakterologicheskie narusheniya v otdalennom posleoperatsionnom periode aortokoronarnogo shuntirovaniya (klinika i terapiya). Psihiatr. psihofarmakoter., 7(4): 14–18.
  • Khaustova O.O. (2018) Na chomu gruntuietsia svidomyi vybir psykhotropnoho preparatu likarem-internistom (na prykladi estsytolapramu). Liky Ukrainy, 3(219): 6.
  • Chazov E.Y. (2003) Depressyia kak faktor razvytyia y prohressyrovanyia serdechno-sosudystыkh zabolevanyi. nedost., 2(1): 6–8.
  • Barefoot J.C., Helms M.J., Mark D.B. et al. (1996) Depression and long-term mortality risk in patients with coronary artery disease. Am. J. Cardiol., 78(6): 613–617.
  • Januzzi J.L.Jr., Stern T.A., Pasternak R.C., DeSanctis R.W. (2000) The influence of anxiety and depression on outcomes of patients with coronary artery disease. Arch. Intern. Med., 160(13): 1913–1921.
  • Kaplan H.I., Sadock B.J. (1998) Pocket handbook of clinical psychiatry Пер. с англ. Т.Б. Дмитриева (ред.). ГЭОТАР-Медиа, Москва, 512 с.
  • Lesperance F., Frasure-Smith N., Talajic M. (1996) Major depression before and after myocardial infarction: its nature and consequences. Psychosom. Med., 58(2): 99–110.
  • Musselman D.L., Evans D.L., Nemeroff C.B. (1998) The relationship of depression to cardiovascular disease: epidemiology, biology, and treatment. Arch. Gen. Psychiatry, 55(7): 580–592.
  • Pająk A., Jankowski P., Kotseva K. et al.; EUROASPIRE Study Group (2013) Depression, anxiety, and risk factor control in patients after hospitalization for coronary heart disease: the EUROASPIRE III Study. Eur. J. Prev. Cardiol., 20(2): 331–340.
  • Tsartsalis D., Dragioti E., Kontoangelos K. et al. (2016) The impact of depression and cardiophobia on quality of life in patients with essential hypertension. Psychiatriki, 27(3): 192–203.
  • World Health Organization (2017) Mental health: Depression (www.who.int/mental_health/management/depression/en/).
  • Zigmond A.S., Snaith R.P. (1983) The hospital anxiety and depression scale. Acta. Psychiatr. Scand., 67(6): 361–370.